title: Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate).
abstract: The analysis of weakly basic drugs such as salmeterol xinafoate (SX) by reverse-phase liquid chromatography remains a problem, particularly when present in combination with other drugs such as steroids and weak acids. This study describes the validation of an assay for a weakly basic drug, salmeterol (SB), its weakly acidic counter-ion, 1-hydroxy-2-naphthoic acid (XA), and the neutral glucocorticoid, fluticasone propionate (FP) using a second-generation silica stationary phase (Inertsil ODS-2). The assay utilized an Inertsil ODS-2 base-deactivated 250 mm x 4.6mm, 5 microm HPLC column, with 75:25 methanol:0.6% aqueous ammonium acetate as the mobile phase. Under these near neutral conditions, SB demonstrated a good peak shape (tailing factor=1.21+/-0.02, n=85). The method provided a short analysis time: XA, t(R)=2.96 min; SB, t(R)=5.23 min and FP, t(R)=7.01 min. The assay displayed good sensitivity for both XA (LOD for SX=0.22 microgmL(-1)) and SB (LOD for SX=0.26 microgmL(-1)). The limit of detection for FP was 0.19 microgmL(-1). Neither of the drugs was found to interfere in the determination of the other and the assay accuracy (% recovery) was high (the recoveries were: 99.58+/-1.85% for XA, 99.49+/-1.88% for SB and 100.24+/-1.28% for FP). The assay reproducibility was determined with a mean coefficient of variance for the five calibration concentrations of XA=0.71+/-0.18%; SB=1.11+/-0.64% and FP=0.92+/-0.14%. Analysis of a pressurized metered dose inhaler formulation demonstrated recovery of the analytes that are within pharmacopoeial limits. It was shown that RP-HPLC was suitable for the high throughput analysis of the combination of SX and FP.
authors.affiliation: Drug Delivery Research Group, Pharmaceutical Science Research Division, King's College London, Stamford Street, London SE1 9NH, UK.
authors.forename: D
authors.initials: D
authors.lastname: Murnane
authors.forename: G P
authors.initials: GP
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Marriott
mesh_terms: D000420:Albuterol / Q000031:analogs & derivatives* / Q000032:analysis; D000730:Androstadienes / Q000032:analysis*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D000068298:Fluticasone; D006863:Hydrogen-Ion Concentration; D007202:Indicators and Reagents; D012015:Reference Standards; D015203:Reproducibility of Results; D000068299:Salmeterol Xinafoate
chemical_list: D000730:Androstadienes; D007202:Indicators and Reagents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol